Equity Overview
Price & Market Data
Price: $3.91
Daily Change: -$0.04 / 1.02%
Range: $3.77 - $4.06
Market Cap: $7,059,162
Volume: 62,114
Performance Metrics
1 Week: -14.80%
1 Month: -10.38%
3 Months: -68.10%
6 Months: -87.47%
1 Year: -77.18%
YTD: -85.24%
Company Details
Employees: 13
Sector: Health technology
Industry: Medical specialties
Country: United States
Details
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.